Novavax (NVAX): Un Nuevo Comienzo

 Doses of Novavax’s updated protein-based non-mRNA COVID vaccine arrived in the U.S. today and are ready to distribute for the fall vaccination campaign, pending FDA and CDC action

When authorized, Novavax's protein-based vaccine candidate will be the only non-mRNA COVID vaccine available in the U.S.

Doses of Novavax’s updated protein-based non-MRNA COVID-19 Vaccine, Adjuvanted arrived in the U.S. today and will be ready for release pending Emergency Use Authorization (EUA) and recommendation from the U.S. Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices (CDC) (ACIP) and the CDC. Novavax will present the latest data on its vaccine at ACIP’s September 12, 2023, meeting to discuss fall COVID vaccination.

Lo que dicen de mañana es una presentación que tiene Novavax.
Hoy tienen una a las 22:30 hora española y mañana la otra.

Novavax’s updated XBB version of its COVID vaccine is currently under review by the U.S. Food and Drug Administration (FDA) for EUA to prevent COVID-19 in individuals aged 12 and older. Novavax is currently responding to the FDA’s requests to facilitate final review, and timing is ultimately at the discretion of the FDA. 

"Novavax is ready for the commercial delivery of our updated protein-based non-mRNA COVID vaccine this fall, and we are working closely with the FDA on its review of our Emergency Use Authorization application," said John C. Jacobs, President and Chief Executive Officer, Novavax. "Pending FDA authorization and CDC recommendation, Novavax’s vaccine will be widely available in major U.S. pharmacies, through Group Purchasing Organizations and through various government entities such as Vaccines for Children, as an option for individuals aged 12 and older to protect themselves against new variants this fall.”

Novavax is working with other global regulatory authorities, including the European  Medicines Agency and Health Canada, on authorizations for its vaccine. 

Novavax está lista, pero no dicen cuántas dosis han fabricado, ni qué es lo que queda pendiente, ni si han terminado de presentar la solicitud(en principio no, porque están respondiendo a la FDA a preguntas que le hacen), etc, etc, etc...

Básicamente TODO MENTIRAS.
Está todo bien y lo sabemos, sino caería un 60% y lo sabemos.